Immune Design Corp  

(Public, NASDAQ:IMDZ)   Watch this stock  
Find more results for IMDZ
+0.40 (9.41%)
After Hours: 4.55 -0.10 (-2.15%)
Nov 24, 3:32PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.25 - 4.70
52 week 3.78 - 13.05
Open 4.35
Vol / Avg. 599,236.00/1.34M
Mkt cap 223.47M
P/E     -
Div/yield     -
EPS -2.13
Shares 48.06M
Beta 2.51
Inst. own 49%
Nov 1, 2017
Q3 2017 Immune Design Corp Earnings Call - Webcast
Oct 17, 2017
Immune Design Corp. - Special Call - Webcast
Sep 28, 2017
Immune Design Corp at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Sep 7, 2017
Immune Design Corp at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -2600.00% -403.70%
Operating margin -2646.32% -408.85%
EBITD margin - -406.56%
Return on average assets -63.70% -46.42%
Return on average equity -79.06% -52.44%
Employees 50 -
CDP Score - -


1616 Eastlake Ave E Ste 310
SEATTLE, WA 98102-3788
United States - Map
+1-206-6820645 (Phone)
+1-206-6820648 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.

Officers and directors

Edward E. Penhoet Ph., D. Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Carlos V. Paya M.D., Ph.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Stephen R. Brady J.D. Executive Vice President, Strategy & Finance
Age: 47
Bio & Compensation  - Reuters
Sergey Yurasov M.D., Ph.D. Senior Vice President, Clinical Development, and Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Jan Henrik Ter Meule M.D. Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Melanie Morrison Vice President - Oncology Platform Leader
Bio & Compensation  - Reuters
Heidi Petersen Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Wayne R. Gombotz Ph.D. Chief Development Officer
Age: 57
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters
Franklin M. Berger Independent Director
Age: 67
Bio & Compensation  - Reuters